Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)

Introduction and background: Head and neck squamous cell carcinoma (HNSCC) has been increasingly recognized as an immune suppressive malignancy. The efficacy of immune checkpoint inhibitors (ICI’s) in the context of recurrent/metastatic (R/M) setting anticipates the possible integration of immunothe...

Full description

Bibliographic Details
Main Authors: Pierluigi Bonomo, Isacco Desideri, Mauro Loi, Monica Mangoni, Mariangela Sottili, Livia Marrazzo, Cinzia Talamonti, Daniela Greto, Stefania Pallotta, Lorenzo Livi
Format: Article
Language:English
Published: Elsevier 2018-02-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Radiotherapy
Head and neck cancer
Cetuximab
Durvalumab
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630817301027

Internet

http://www.sciencedirect.com/science/article/pii/S2405630817301027

Similar Items